Adagene (NASDAQ: ADAG) — Perfil da empresa, notícias e dados financeiros
Adagene develops innovative cancer immunotherapy treatments, focusing on antibody discovery using advanced technologies.
Adagene
Adagene (NASDAQ:ADAG) specializes in antibody discovery and engineering, focusing on developing innovative solutions for cancer immunotherapy. This company leverages its proprietary Dynamic Precision Library and SAFEbody technologies to create a robust pipeline of clinical and preclinical candidates aimed at addressing unmet medical needs in oncology. Adagene's projects revolve around advancing these candidates through rigorous clinical trials, with the objective of introducing more effective, less toxic cancer therapies. The company's operations span across research and development, clinical trial management, and strategic partnerships to speed up the delivery of their innovative treatments to patients worldwide. Adagene's mission is to transform the landscape of cancer treatment by advancing the frontiers of antibody engineering and immunotherapy.
Resumo
Operações
Produtos e/ou serviços de Adagene
- Dynamic Precision Library (DPL) platform, a technology for creating highly diversified antibody libraries.
- SAFEbody technology, innovating in developing safer and more effective antibody therapies.
- ADG116, an experimental drug targeting advanced solid tumors and lymphomas.
- ADG126, a SAFEbody-based therapeutic agent designed for immune-oncology applications.
- ADG106, a CD137 agonist antibody for treating refractory cancer patients.
- ADG104, an anti-CTLA-4 antibody undergoing clinical trials for its potential in cancer immunotherapy.
equipe executiva do Adagene
- Peter P. LuoCo- Founder, Chairman, CEO and President of R&D
- Man Kin TamCFO & Director
- Ling ZhouExecutive Director & Head of Human Resources
- Qinghai ZhaoChief Manufacturing Officer
- Mickael Chane-DuChief Strategy Officer
- Yan LiSenior Vice President of Bioinformatics & Information Technology
- Xiaohong SheSenior VP & Head of Clinical Operations
- Guizhong LiuSenior Vice President of Early Drug Discovery
- Alexander GoergenVP & Head of Business Development
- Jiping ZhaExecutive Vice President of Clinical Development
Últimas notícias sobre a Adagene
Principais indicadores financeiros
Resultados divulgados pela Adagene, em USD.
- Cap. de mercado
- 173,2 mi
- Receita (TTM)
- 9,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -220.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,7 mi | -21,4 mi | -17,6 mi | |
| 103,2 mil | -36 mi | -33,4 mi | |
| 18,1 mi | -23,7 mi | -18,9 mi | |
| 9,3 mi | -83,9 mi | -80 mi |